Intellia's data on its HAE gene-editing treatment has been released, with some outlets reporting that it has impressed wall street, leading to a jump in NTLA stock. However, other reports indicate that the stock has actually fallen, despite the data being considered strong. The company has initiated a rolling biologics license application.